Targeting the survival cascade of B-cells in lymphoid malignancies
The standard of care for DLBCL and double-hit lymphoma
Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors
Why do many MM patients relapse after being treated with targeted therapy?
Expanding role for MRD in managing MM